These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21035953)

  • 1. A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
    Sato T; Ozawa H; Hatate K; Onosato W; Naito M; Nakamura T; Ihara A; Koizumi W; Hayakawa K; Okayasu I; Yamashita K; Watanabe M
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):677-83. PubMed ID: 21035953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.
    Sato T; Kokuba Y; Koizumi W; Hayakawa K; Okayasu I; Watanabe M
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1442-7. PubMed ID: 17855009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1).
    Sato T; Hayakawa K; Tomita N; Noda M; Kamikonya N; Watanabe T; Kato D; Sakai Y; Hiraoka M; Shimada M; Ikushima H; Baba H; Oya N; Oya M; Nemoto-Murofushi K; Takeuchi M; Watanabe M
    Radiother Oncol; 2016 Aug; 120(2):222-7. PubMed ID: 27317556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
    Nakamura T; Yamashita K; Sato T; Ema A; Naito M; Watanabe M
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):547-55. PubMed ID: 24929164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
    Jung M; Shin SJ; Koom WS; Jung I; Keum KC; Hur H; Min BS; Baik SH; Kim NK; Kim H; Lim JS; Hong SP; Kim TI; Roh JK; Park YS; Ahn JB
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1015-22. PubMed ID: 26581140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer.
    Choi HJ; Kim NK; Keum KC; Cheon SH; Shin SJ; Baik SH; Choen JH; Rha SY; Roh JK; Jeung HC; Chung HC; Ahn JB
    Radiother Oncol; 2008 Jun; 87(3):361-6. PubMed ID: 18439695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
    Horisberger K; Treschl A; Mai S; Barreto-Miranda M; Kienle P; Ströbel P; Erben P; Woernle C; Dinter D; Kähler G; Hochhaus A; Post S; Willeke F; Wenz F; Hofheinz RD;
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1487-93. PubMed ID: 19131187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neoadjuvant chemoradiotherapy for locally advanced rectal cancer].
    Kuriu Y; Kokuba Y; Murayama Y; Komatsu S; Shiozaki A; Ikoma H; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Otsuji E
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):1951-3. PubMed ID: 23267940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of preoperative concurrent chemoradiotherapy with S-1 for locally advanced, resectable rectal adenocarcinoma.
    Sadahiro S; Suzuki T; Tanaka A; Okada K; Kamijo A; Murayama C; Akiba T; Nakayama Y
    Oncology; 2011; 81(5-6):306-11. PubMed ID: 22156392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II Study of Preoperative Chemoradiotherapy With TEGAFIRI for Locally Advanced Rectal Cancer.
    Kawai K; Sunami E; Hata K; Tanaka T; Nishikawa T; Otani K; Sasaki K; Nozawa H
    Clin Colorectal Cancer; 2018 Sep; 17(3):240-246. PubMed ID: 29934092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
    Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of preoperative chemoradiation with s-1 and oxaliplatin in patients with locally advanced resectable rectal cancer.
    Hong YS; Lee JL; Park JH; Kim JH; Yoon SN; Lim SB; Yu CS; Kim MJ; Jang SJ; Lee JS; Kim JC; Kim TW
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):684-9. PubMed ID: 20452140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study.
    Hong YS; Kim DY; Lim SB; Choi HS; Jeong SY; Jeong JY; Sohn DK; Kim DH; Chang HJ; Park JG; Jung KH
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1171-8. PubMed ID: 20605355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer.
    Shin SJ; Kim NK; Keum KC; Kim HG; Im JS; Choi HJ; Baik SH; Choen JH; Jeung HC; Rha SY; Roh JK; Chung HC; Ahn JB
    Radiother Oncol; 2010 Jun; 95(3):303-7. PubMed ID: 20211505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
    Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
    Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
    Hata T; Fukunaga M; Murata K; Uemura Y; Fukuzaki T; Ota H; Ohue M; Ohnishi T; Tanaka N; Takemasa I; Mizushima T; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1657-63. PubMed ID: 23543294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.
    Mohiuddin M; Winter K; Mitchell E; Hanna N; Yuen A; Nichols C; Shane R; Hayostek C; Willett C;
    J Clin Oncol; 2006 Feb; 24(4):650-5. PubMed ID: 16446336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
    Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
    ; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
    J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan.
    Kimura K; Yamano T; Igeta M; Imada A; Jihyung S; Babaya A; Hamanaka M; Kobayashi M; Tsukamoto K; Noda M; Ikeda M; Tomita N
    Cancer Sci; 2018 Dec; 109(12):3934-3942. PubMed ID: 30246377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.